Ratios Of Dose Equivalents Research Articles

Response of personal dosemeters on various age-specific anthropometric phantoms under external irradiation applied to areas affected by the 2011 Fukushima Daiichi nuclear accident.

We experimentally obtained the responses of two personal dosemeters (PDs, D-shuttle and Dose-i) attached on five age-specific phantoms under rotational irradiation geometry, which simulated an environment that was radiologically affected by the 2011 Fukushima nuclear accident using of a 137Cs source. Although the PD responses showed an angular phase shift by the PD position on the phantoms, the angular dependence was small when the contamination was widely distributed. The PD responses decreased as much as ~10% with the increase in the phantoms' body size. Although there were ~17% variations in the PD/ADE (ambient dose equivalent) ratio depending on the different PDs, this variation was due to the fact that D-shuttle was calibrated with the inclusion of a safety margin. The PD/ADE ratios were similar to the effective dose to ADE ratios for corresponding age-specific phantoms. Our results suggest that these two PDs can provide reasonable estimates for age-dependent effective doses.

Neutron measurements from the interaction of a thick Ta target with protons at different energies

Neutron dosimetry and spectrometry with a Ta target is of concern in an accelerator environment considering its enormous use in a proton accelerator. The Ta target has a unique advantage considering the generation of short half lived radionuclides upon interaction with protons. This advantage extends its use as the beam stopping material at various locations of an accelerator. However, this target has a varied range of reactions to produce neutrons and prompt gammas depending on proton energies. So in the present work, the neutron spectra were generated at various incident proton energies and neutron ambient dose equivalents were estimated close to the target projectile interaction at 90°with respect to the incident beam direction. A comparison of the spectral nature and doses were also done with measurements made by our earlier studies carried out at 0°. The comparison clearly showed that, apart from an increase in the low energy neutron yields at 90°, the overall yield distribution remains similar at both 0°and 90°angles with respect to the incoming beam direction. The ratio of the ambient neutron dose equivalent is found to reduce by a factor of 3–4 at 90°compared to 0°over the entire incident proton energy range. So, the dose equivalent ratio at two angles can be considered as independent of the incident projectile energy.

Assessment of the indoor-to-outdoor ratio of dose rates in and around the historic objects in Bosnia and Herzegovina

This paper deals with the first study of the indoor to outdoor ambient dose equivalent rates ratio measured in and around the historic objects at various locations in Bosnia and Herzegovina. The IndentiFINDER-N spectrometer results showed a positive correlation between the dose rates inside and outside the studied objects while the Radiagem™2000 survey meter indicated larger fluctuations. It was found that the average indoor to outdoor dose rate ratio of 1.2 for the historic objects was close to the ratio for the dwellings made of materials having nearly the same radioactivity content as the surrounding soil.

Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset Cardiotoxicity

Anthracyclines are part of many effective pediatric cancer treatment protocols. Most pediatric oncology treatment groups assume that the hematologic toxicity of anthracycline agents is equivalent to their cardiotoxicity; for example, Children's Oncology Group substitution rules consider daunorubicin and epirubicin isoequivalent to doxorubicin, whereas mitoxantrone and idarubicin are considered 4 to 5 times as toxic as doxorubicin. To determine optimal dose equivalence ratios for late-onset cardiomyopathy between doxorubicin and other anthracyclines or the anthraquinone mitoxantrone. This multicenter cohort study of childhood cancer survivors who survived 5 or more years analyzed data pooled from 20 367 participants in the Childhood Cancer Survivor Study treated from 1970 to 1999, 5741 participants in the Dutch Childhood Oncology Group LATER study diagnosed between 1963 and 2001, and 2315 participants in the St Jude Lifetime study treated from 1962 to 2005. Cumulative doses of each agent (the anthracyclines doxorubicin, daunorubicin, epirubicin, and idarubicin; and the anthraquinone mitoxantrone) along with chest radiotherapy exposure were abstracted from medical records. Cardiomyopathy (severe, life-threatening, or fatal) by 40 years of age. Agent-specific Cox proportional hazards models evaluated cardiomyopathy risk, adjusting for chest radiotherapy, age at cancer diagnosis, sex, and exposure to anthracyclines or to an anthraquinone. An agent-specific cardiomyopathy equivalence ratio (relative to doxorubicin) was estimated for each dose category as a ratio of the hazard ratios, and then a weighted mean determined the overall agent-specific equivalence ratio across all dose categories. Of 28 423 survivors (46.4% female; median age at cancer diagnosis 6.1 years [range, 0.0-22.7 years]), 9330 patients received doxorubicin, 4433 received daunorubicin, 342 received epirubicin, 241 received idarubicin, and 265 received mitoxantrone. After a median follow-up of 20.0 years (range, 5.0-40.0 years) following receipt of a cancer diagnosis, 399 cardiomyopathy cases were observed. Relative to doxorubicin, the equivalence ratios were 0.6 (95% CI, 0.4-1.0) for daunorubicin, 0.8 (95% CI, 0.5-2.8) for epirubicin, and 10.5 (95% CI, 6.2-19.1) for mitoxantrone. Outcomes were too rare to generate idarubicin-specific estimates. Ratios based on a continuous linear dose-response relationship were similar for daunorubicin (0.5 [95% CI, 0.4-0.7]) and epirubicin (0.8 [95% CI, 0.3-1.4]). The relationship between mitoxantrone and doxorubicin appeared better characterized by a linear exponential model. In a large data set assembled to examine long-term cardiomyopathy risk in childhood cancer survivors, daunorubicin was associated with decreased cardiomyopathy risk vs doxorubicin, whereas epirubicin was approximately isoequivalent. By contrast, the current hematologic-based doxorubicin dose equivalency of mitoxantrone (4:1) appeared to significantly underestimate the association of mitoxantrone with long-term cardiomyopathy risk.

Don’t Hang Up Your Lead, Yet

Three botulinum neurotoxin type A (BoNT/A) products, incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA, all manufactured by different methods, are employed in clinical practice. Comparing the three BoNT/A products is difficult because their concentrations and volumes differ and the precise dose equivalence ratio is not known. We aimed to compare the neurotoxic potencies by a systematic analysis of injected volume and dose.The potency of BoNT in inducing hind limb paresis was assessed by analyzing the wheel-running performance of mice. To standardize the volume, the effect of an identical dose of incobotulinumtoxinA dissolved in different volumes of saline (15, 10, 5, and 2 μl) was studied in four groups of mice (n = 13–15). The potencies of the BoNT products were then compared by injecting identical volumes (10 μl) containing different doses into both hind leg muscles.Mice injected with incobotulinumtoxinA showed a volume-dependent reduction in wheel-running, with larger volumes inducing more intense paresis. A standardized volume containing the same number of mouse units of the BoNT/A products produced different degrees of paresis. The conversion ratio of incobotulinumtoxinA and onabotulinumtoxinA is estimated to be between 1:0.75 and 1:0.5. OnabotulinumtoxinA displayed a two-fold greater potency than abobotulinumtoxinA. Doses of onabotulinumtoxinA and abobotulinumtoxinA that produce an identical severity of pareses even result in the same duration of pareses.This wheel-running assay allows one to compare the neurotoxic potency of different volumes and doses of the BoNT products in vivo. Our results argue against common clinical practice because incobotulinumtoxinA and onabotulinumtoxinA are not readily interchangeable and a two-fold dose of abobotulinumtoxinA is needed to induce an effect identical to onabotulinumtoxinA. In addition, this emphasizes that the duration of BoNT-induced effect is the same as long as equipotent doses of BoNT are injected.

In-vivo comparison of the neurotoxic potencies of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA

Three botulinum neurotoxin type A (BoNT/A) products, incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA, all manufactured by different methods, are employed in clinical practice. Comparing the three BoNT/A products is difficult because their concentrations and volumes differ and the precise dose equivalence ratio is not known. We aimed to compare the neurotoxic potencies by a systematic analysis of injected volume and dose.The potency of BoNT in inducing hind limb paresis was assessed by analyzing the wheel-running performance of mice. To standardize the volume, the effect of an identical dose of incobotulinumtoxinA dissolved in different volumes of saline (15, 10, 5, and 2μl) was studied in four groups of mice (n=13–15). The potencies of the BoNT products were then compared by injecting identical volumes (10μl) containing different doses into both hind leg muscles.Mice injected with incobotulinumtoxinA showed a volume-dependent reduction in wheel-running, with larger volumes inducing more intense paresis. A standardized volume containing the same number of mouse units of the BoNT/A products produced different degrees of paresis. The conversion ratio of incobotulinumtoxinA and onabotulinumtoxinA is estimated to be between 1:0.75 and 1:0.5. OnabotulinumtoxinA displayed a two-fold greater potency than abobotulinumtoxinA. Doses of onabotulinumtoxinA and abobotulinumtoxinA that produce an identical severity of pareses even result in the same duration of pareses.This wheel-running assay allows one to compare the neurotoxic potency of different volumes and doses of the BoNT products in vivo. Our results argue against common clinical practice because incobotulinumtoxinA and onabotulinumtoxinA are not readily interchangeable and a two-fold dose of abobotulinumtoxinA is needed to induce an effect identical to onabotulinumtoxinA. In addition, this emphasizes that the duration of BoNT-induced effect is the same as long as equipotent doses of BoNT are injected.

Dose assessment for the fetus considering scattered and secondary radiation from photon and proton therapy when treating a brain tumor of the mother

The goal of this work was to determine the scattered photon dose and secondary neutron dose and resulting risk for the sensitive fetus from photon and proton radiotherapy when treating a brain tumor during pregnancy. Anthropomorphic pregnancy phantoms with three stages (3-, 6-, 9-month) based on ICRP reference parameters were implemented in Monte Carlo platform TOPAS, to evaluate the scattered dose and secondary neutron dose and dose equivalent. To evaluate the dose equivalent, dose averaged quality factors were considered for neutrons. This study compared three treatment modalities: passive scattering and pencil beam scanning proton therapy (PPT and PBS) and 6-MV 3D conformal photon therapy. The results show that, for 3D conformal photon therapy, the scattered photon dose equivalent to the fetal body increases from 0.011 to 0.030 mSv per treatment Gy with increasing stage of gestation. For PBS, the neutron dose equivalent to the fetal body was significantly lower, i.e. increasing from 1.5 × 10−3 to 2.5 × 10−3 mSv per treatment Gy with increasing stage of gestation. For PPT, the neutron dose equivalent of the fetus decreases from 0.17 to 0.13 mSv per treatment Gy with the growing fetus. The ratios of dose equivalents to the fetus for a 52.2 Gy(RBE) course of radiation therapy to a typical CT scan of the mother’s head ranged from 3.4–4.4 for PBS, 30–41 for 3D conformal photon therapy and 180–500 for PPT, respectively. The attained dose to a fetus from the three modalities is far lower than the thresholds of malformation, severe mental retardation and lethal death. The childhood cancer excessive absolute risk was estimated using a linear no-threshold dose-response relationship. The risk would be 1.0 (95% CI: 0.6, 1.6) and 0.1 (95% CI: −0.01, 0.52) in 105 for the 9-month fetus for PBS with a prescribed dose of 52.2 Gy(RBE). The increased risks for PPT and photon therapy are about two and one orders of magnitude larger than that for PBS, respectively. We can conclude that a pregnant woman with a brain tumor could be treated with pencil beam scanning with acceptable risks to the fetus.

Switch from abobotulinumtoxinA (Dysport®) to incobotulinumtoxinA (Xeomin®) botulinum toxin formulation: a review of 257 cases.

To explore the dose equivalence ratio and treatment costs for abobotulinumtoxinA and incobotulinumtoxinA for patients with focal dystonias. Patient chart review. Adult patients with blepharospasm (n = 19), cervical dystonia (n = 122), hemifacial spasm (n = 91) or segmental/generalized dystonia (n = 19) at a neurology outpatient clinic. Patients were switched from established abobotulinumtoxinA therapy to incobotulinumtoxinA at a ~4:1 unit ratio. Dose requirements, injection intervals, treatment efficacy, and adverse events were evaluated for a period of ≥ 1 year. Patients were switched from abobotulinumtoxinA to incobotulinumtoxinA with a mean dose ratio of 4.07 (standard deviation (SD) 0.50). After switching, incobotulinumtoxinA dose requirements remained stable; the mean (SD) dose ratio at the end of the review period (52-219 weeks after switching) was 3.89 (SD 0.58). Injection intervals also remained stable after switching. Adverse events were injection site pain (n = 45) and bruising (n = 4). Five patients (2.0%) discontinued incobotulinumtoxinA treatment: 4 stopped receiving injections, and 1 reverted to abobotulinumtoxinA. Switching to incobotulinumtoxinA reduced the mean toxin expenditure to 76.7% of the cost of abobotulinumtoxinA. For patients with conditions commonly treated in dystonia clinics, switching from abobotulinumtoxinA to incobotulinumtoxinA, given at equivalent doses (~4:1 unit ratio) at similar intervals, was effective, well tolerated and achieved cost savings.

A retrospective evaluation of the efficacy of intravenous bumetanide and comparison of potency with furosemide.

The potency of intravenous bumetanide to furosemide using a ratio of 1:40 has been suggested; however, there are little data supporting this ratio. Recent drug shortages required the use of bumetanide in a large patient population, enabling further characterization of the efficacy of IV bumetanide. The primary objective of this study was to estimate a dose-response effect of IV bumetanide on urine output (UOP) in all patients that received 48 hours of therapy as well as in a subgroup of patients with heart failure (HF). This subgroup was used to compare the potency of bumetanide with furosemide. A secondary safety objective described electrolyte replacement required during therapy. This was a single-center retrospective study examining the dose-response effect of IV bumetanide in patients receiving at least 48 hours of intermittent (iIV) or continuous (cIV) dosing, measured by UOP per mg of drug received (mL/mg). The potency of IV bumetanide was compared with furosemide in a subset of patients with HF using pre-existing data. The safety of IV bumetanide was analyzed by quantifying electrolyte replacement received during the study period. The primary outcome was higher in the iIV group (n=93) at 1273 ± 844 mL/mg compared with the cIV group (n=16) at 749 ± 370 mL/mg (P=0.002). Among patients with HF who received furosemide (iIV n=30, cIV n=26) or bumetanide (iIV n=30, cIV n=3), a potency ratio of 41:1 was found for the iIV group and 34:1 for all patients with HF. There was no significant difference in electrolyte replacement between groups. A greater response was seen with intermittent bumetanide compared with continuous infusion bumetanide. This study supports the 40:1 dose equivalence ratio (furosemide:bumetanide) in patients with HF receiving at least 48 hours of intravenous intermittent bumetanide.

LET spectrometry of 14 MeV (D–T) neutrons using CR-39 track detectors

Linear energy transfer (LET) spectrum in water in the range of 12keV/μm to 382keV/μm due to 14MeV (D–T) neutrons is estimated using the track size parameters in two different types of CR-39 track detectors, viz. Intercast (1.5mm) and Pershore (0.5mm). Another set of CR-39s (Intercast) combined with 1mm polyethylene (PE) radiators is exposed to study the effect of enhanced recoils on the LET spectrum. The detection efficiencies for all these cases and the enhancement ratio due to PE radiator are determined. Using this LET spectrum, the microdosimetric spectra of absorbed doses and dose equivalents are estimated based on the Q–L conversion factors as given in ICRP 60. The shape of the LET spectra are found to be similar in all the cases, however, the dose equivalents obtained with the CR-39+PE radiator is about 20% more than the other detectors without PE. The ratios of dose equivalents obtained from LET spectra (HLET) and the ambient dose equivalent (H*(10)) obtained from fluence-to-dose equivalent conversion factors (ICRP 74) for 14MeV neutrons are used to estimate the dose response of the detectors. H*(10) is also measured using a neutron rem meter, the response of which is found to be about 23% less than the actual dose.

Evaluating botulinum toxin products for clinical use requires accurate, complete, and unbiased data

Evaluating botulinum toxin products for clinical use requires accurate, complete, and unbiased data

Comparison of space radiation doses inside the Matroshka-torso phantom installed outside the ISS with the doses in a cosmonaut body in Orlan-M spacesuit during EVA

In the framework of the Russian space experiment Matroshka-R, in years 2004–2005 a special study of the dose distribution in anthropomorphic phantom was carried out. In the study, the phantom was installed on the outer surface of the International Space Station (ISS) in a special container that simulates the spacesuit shielding (Matroshka-Torso experiment). The purpose of this work is to compare the space radiation doses inside the Matroshka-Torso phantom with the doses in a cosmonaut body in Orlan-M spacesuit during an extra-vehicular activity (EVA) in similar conditions. For the calculation of the corresponding shielding functions, a geometrical model and technical description of the Matroshka-Torso phantom and container are used as well as technical description of the Orlan-M spacesuit and the results of its shielding study in an on ground gamma-transmission experiment. Dose calculations are made by using depth-dose curves for galactic cosmic rays, and trapped protons and electrons, the latter are taken from АЕ-8/АР-8 model. The calculated ratios of dose equivalents in critical organs of the Orlan-M spacesuit to those in Matroshka-Torso H( Orlan-M)/ H( Matroshka-Torso) vary from 0.1 to 1.8 as dependent on the selected critical organ and solar cycle phase. The results obtained should be taken into account when transferring the data of the Matroshka-Torso experiment to the real EVA radiation conditions in Orlan-M spacesuit.

Biological activity of two botulinum toxin type A complexes (Dysport® and Botox®) in volunteers

Despite extensive clinical experience and published data regarding botulinum toxin, questions remain about the clinical substitution of one botulinum toxin formulation for another. In the case of Dysport® and Botox®, doseequivalence ratios ranging from 1:1 to 6:1 (Dysport:Botox) have been advocated. This dose-ranging, electroneurographic study investigated the dose equivalence, diffusion characteristics (spread) and safety of these two type-A toxins in 79 volunteers. Dysport and Botox caused significant and similar reductions in compound muscle action potential (CMAP) amplitude in the target muscle (extensor digitorum brevis, EDB) 2 weeks after injection, with effects persisting to the 12-week timepoint. For both products, the reduction in amplitude was increased with increasing doses and with increasing concentration. The effects of toxin on neighbouring muscles were much smaller and of a shorter duration than those on the target muscle, implying a modest spread of toxin. Unlike the target muscle, the effects were greater with the higher volume, suggesting this volume led to greater diffusion from the EDB. No adverse events were reported. Statistical modelling with CMAP amplitude data from the target muscle gave a bioequivalence of 1.57 units of Dysport:1 unit of Botox (95 % CI: 0.77–3.20 units). The data indicate that a dose-equivalence ratio of 3:1 was within the statistical error limits, but ratios over 3:1 are too high.

Biological activity of two botulinum toxin type A complexes (Dysport® and Botox®) in volunteers

Despite extensive clinical experience and published data regarding botulinum toxin, questions remain about the clinical substitution of one botulinum toxin formulation for another. In the case of Dysport and Botox, dose-equivalence ratios ranging from 1:1 to 6:1 (Dysport:Botox) have been advocated. This dose-ranging, electroneurographic study investigated the dose equivalence, diffusion characteristics (spread) and safety of these two type-A toxins in 79 volunteers. Dysport and Botox caused significant and similar reductions in compound muscle action potential (CMAP) amplitude in the target muscle (extensor digitorum brevis, EDB) 2 weeks after injection, with effects persisting to the 12-week timepoint. For both products, the reduction in amplitude was increased with increasing doses and with increasing concentration. The effects of toxin on neighbouring muscles were much smaller and of a shorter duration than those on the target muscle, implying a modest spread of toxin. Unlike the target muscle, the effects were greater with the higher volume, suggesting this volume led to greater diffusion from the EDB. No adverse events were reported. Statistical modelling with CMAP amplitude data from the target muscle gave a bioequivalence of 1.57 units of Dysport:1 unit of Botox (95 % CI: 0.77-3.20 units). The data indicate that a dose-equivalence ratio of 3:1 was within the statistical error limits, but ratios over 3:1 are too high.

Biological activity of Dysport ® and Botox ® in the human EDB muscle: A double-blind, randomized, dose-ranging study

Although the potency of botulinum toxin type A preparations is expressed in mouse LD50 units, differences in the excipients used mean that the units from the assay used for Dysport are different from those from the assay used for Botox. Despite extensive clinical experience and published data, this remains controversial, with published dose-equivalence ratios ranging from 1:1 to 6:1 (Dysport: Botox). This dose-ranging, electroneurographic study investigated the dose equivalence, diffusion characteristics (spread) and safety of these two type-A toxins in 79 volunteers. Dysport and Botox caused significant and similar reductions in compound muscle action potential (CMAP) amplitude in the target muscle (extensor digitorum brevis, EDB) 2–12 weeks after injection. For both products, the reduction in amplitude increased with increasing doses and with increasing concentration. The effects of toxin on neighboring muscles were much smaller than those on the target muscle, implying some spread of toxin. These effects were greater with the higher volume, suggesting this volume led to greater diffusion from the EDB. No adverse events were reported. Statistical modelling with CMAP amplitude data from the target muscle gave a bioequivalence of 1.57 units of Dysport:1 unit of Botox (95% CI: 0.77–3.20 units). A dose-equivalence ratio of 3:1 was within the statistical error limits, but ratios over 3:1 are too high.

Photonuclear dose calculations for high-energy photon beams from Siemens and Varian linacs.

The dose from photon-induced nuclear particles (neutrons, protons, and alpha particles) generated by high-energy photon beams from medical linacs is investigated. Monte Carlo calculations using the MCNPX code are performed for three different photon beams from two different machines: Siemens 18 MV, Varian 15 MV, and Varian 18 MV. The linac head components are simulated in detail. The dose distributions from photons, neutrons, protons, and alpha particles are calculated in a tissue-equivalent phantom. Neutrons are generated in both the linac head and the phantom. This study includes (a) field size effects, (b) off-axis dose profiles, (c) neutron contribution from the linac head, (d) dose contribution from capture gamma rays, (e) phantom heterogeneity effects, and (f) effects of primary electron energy shift. Results are presented in terms of absolute dose distributions and also in terms of DER (dose equivalent ratio). The DER is the maximum dose from the particle (neutron, proton, or alpha) divided by the maximum photon dose, multiplied by the particle quality factor and the modulation scaling factor. The total DER including neutrons, protons, and alphas is about 0.66 cSv/Gy for the Siemens 18 MV beam (10 cm x 10 cm). The neutron DER decreases with decreasing field size while the proton (or alpha) DER does not vary significantly except for the 1 cm x 1 cm field. Both Varian beams (15 and 18 MV) produce more neutrons, protons, and alphas particles than the Siemens 18 MV beam. This is mainly due to their higher primary electron energies: 15 and 18.3 MeV, respectively, vs 14 MeV for the Siemens 18 MV beam. For all beams, neutrons contribute more than 75% of the total DER, except for the 1 cm x 1 cm field (approximately 50%). The total DER is 1.52 and 2.86 cSv/Gy for the 15 and 18 MV Varian beams (10 cm x 10 cm), respectively. Media with relatively high-Z elements like bone may increase the dose from heavy charged particles by a factor 4. The total DER is sensitive to primary electron energy shift. A Siemens 18 MV beam with 15 MeV (instead of 14 MeV) primary electrons would increase by 40% the neutron DER and by 210% the proton + alpha DER. Comparisons with measurements (neutron yields from different materials and neutron dose equivalent) are also presented. Using the NCRP risk assessment method, we found that the dose equivalent from leakage neutrons (at 50-cm off-axis distance) represent 1.1, 1.1, and 2.0% likelihood of fatal secondary cancer for a 70 Gy treatment delivered by the Siemens 18 MV, Varian 15 MV, and Varian 18 MV beams, respectively.

Chlorpromazine equivalent doses for the newer atypical antipsychotics.

Several clinical and research applications require an estimation of therapeutic dose equivalence across antipsychotic medications. Since the advent of the newer atypical antipsychotics, new dose equivalent estimations have been needed. The reported minimum effective dose was identified for each newer atypical antipsychotic medication and for haloperidol across all available fixed-dose placebo-controlled studies. Reported minimum effective dose equivalence ratios to haloperidol were then converted to chlorpromazine equivalents using the "2 mg of haloperidol equals 100 mg of chlorpromazine" convention. To identify the fixed-dose studies, the following sources were searched until June 2002: MEDLINE, the bibliographies of identified reports, published meta-analyses and reviews, Cochrane reviews, Freedom of Information Act material available from the Food and Drug Administration, and abstracts from several scientific meetings from 1997 to 2002. Doses equivalent to 100 mg/day of chlorpromazine were 2 mg/day for risperidone, 5 mg/day for olanzapine, 75 mg/day for quetiapine, 60 mg/day for ziprasidone, and 7.5 mg/day for aripiprazole. These equivalency estimates may be useful for clinical and research purposes. The source of the dose equivalency estimation is evidence-based and consistent across medication.

A comparison of different neutron spectroscopy systems at the reactor facility VENUS

The VENUS facility is a zero-power research reactor mainly devoted to studies on LWR fuels. Localised high-neutron rates were found around the reactor, with a neutron/gamma dose equivalent rate ratio as high as three. Therefore, a study of the neutron dosimetry around the reactor was started some years ago. During this study, several methods of neutron spectroscopy were employed and a study of individual and ambient dosemeters was performed. A first spectrometric measurement was done with the IPSN multisphere spectrometer in three positions around the reactor. Secondly, the ROSPEC spectrometer from the Fraunhofer Institut was used. The spectra were also measured with the bubble interactive neutron spectrometer. These measurements were compared with a numerical simulation of the neutron field made with the code TRIPOLI-3. Dosimetric measurements were made with three types of personal neutron dosemeters: an albedo type, a track etch detector and a bubble detector.

An overnight switch to ropinirole therapy in patients with Parkinson's disease. Short communication.

Patients with Parkinson's disease (n = 68) switched from pergolide or bromocriptine to ropinirole overnight (dose equivalence ratios 1:6 and 10:6, respectively). The activities of daily living score for the Unified Parkinson's Disease Rating Scale (UPDRS) was significantly improved 4 weeks after the bromocriptine-ropinirole switch. All other UPDRS scores, including that for the side-effect component, were not significantly different after either switch. Overnight switching may be a safe therapeutic approach that may reduce hospitalisation and related socio-economic costs.

Measurement of photoneutron doses in and out of high-energy X-ray beam of a SATURNE-20 medical linear accelerator by ECE polycarbonate detectors

Photoneutron contaminations in and out of high energy X-ray beams of the medical linear accelerator SATURNE 20 (CGR) of the Radiotherapy Department of Omeed Hospital in Isfahan, Iran, have been determined using 250 μm polycarbonate (PC) dosimeters, in strips or in sheets, processed by electrochemical etching (ECE) using specially designed ECE chambers to etch larger sheets. A two dimensional or topographical distribution of neutron contamination was also determined in a full size beam. The neutron dose equivalents (Hn) in the beam of 18 MV X-rays at 80 cm FSD were determined to be linear functions of X-ray dose equivalents (Hx) up to 1400 cSv. The distribution of the Hn at different X-ray doses showed bell-shape profiles with maxima at the isocenter. The ratios of dose equivalents of neutrons to those of X-rays increased as the field size increased having values of 0.22%, 0.28%, 0.31% and 0.37% for field sizes of 10×10, 20×20, 30×30, and 40×40 cm 2 respectively. Although such neutron dose equivalents can be corrected for patient treatment, it can cause radiation protection problems for workers where the design of the facility is not well planned.